PALI

SEC source: 0001209191-21-055729 · doc4.xml · nonDerivative · entry 3

Trenschel Robert J. · CIK 0001849917 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,457

SEC source: 0001209191-21-055729 · doc4.xml · nonDerivative · entry 2

Trenschel Robert J. · CIK 0001849917 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,457

SEC source: 0001209191-21-055729 · doc4.xml · nonDerivative · entry 1

Trenschel Robert J. · CIK 0001849917 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,750

SEC source: 0001209191-21-053803 · doc4.xml · nonDerivative · entry 2

Finley John David · CIK 0001851034 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,396

SEC source: 0001209191-21-053803 · doc4.xml · nonDerivative · entry 1

Finley John David · CIK 0001851034 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,996

SEC source: 0001209191-21-029080 · doc4.xml · derivative · entry 7

Trenschel Robert J. · CIK 0001849917 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Yuma Regional Medical Center

Disclosed balance after: 1,223

Underlying: Common Stock · 1,223 shares

Expires 2030-10-15

F11 · price: Received in the Merger in exchange for a warrant to purchase 45,000 shares of LBS common stock for $0.73 per share.

F2 · ownership.nature: The Reporting Person is the President and Chief Executive Officer of Yuma Regional Medical Center and shares voting and investment power over the securities held by Yuma Regional Medical Center.

SEC source: 0001209191-21-029080 · doc4.xml · derivative · entry 6

Trenschel Robert J. · CIK 0001849917 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Yuma Regional Medical Center

Disclosed balance after: 13,595

Underlying: Common Stock · 13,595 shares

Expires 2029-08-15

F10 · price: Received in the Merger in exchange for a warrant to purchase 500,000 shares of LBS common stock for $1.12 per share.

F2 · ownership.nature: The Reporting Person is the President and Chief Executive Officer of Yuma Regional Medical Center and shares voting and investment power over the securities held by Yuma Regional Medical Center.

SEC source: 0001209191-21-029080 · doc4.xml · derivative · entry 5

Trenschel Robert J. · CIK 0001849917 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Yuma Regional Medical Center

Disclosed balance after: 40,785

Underlying: Common Stock · 40,785 shares

Expires 2029-03-08

F9 · price: Received in the Merger in exchange for a warrant to purchase 1,500,000 shares of LBS common stock for $1.12 per share.

F2 · ownership.nature: The Reporting Person is the President and Chief Executive Officer of Yuma Regional Medical Center and shares voting and investment power over the securities held by Yuma Regional Medical Center.

SEC source: 0001209191-21-029080 · doc4.xml · derivative · entry 4

Trenschel Robert J. · CIK 0001849917 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,406

Underlying: Common Stock · 4,406 shares

Expires 2030-07-10

F8 · price: Received in the Merger in exchange for a stock option to acquire 162,069 shares of LBS common stock for $0.73 per share.

F7 · derivative.exercise_date: The stock option vests according to the following schedule: 25% of the shares underlying the option vests on the grant date and the remaining 75% vests in three equal quarterly installments thereafter beginning on September 30, 2020.

SEC source: 0001209191-21-029080 · doc4.xml · derivative · entry 3

Trenschel Robert J. · CIK 0001849917 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,298

Underlying: Common Stock · 1,298 shares

Expires 2029-06-19

F6 · price: Received in the Merger in exchange for a stock option to acquire 47,758 shares of LBS common stock for $1.12 per share.

F5 · derivative.exercise_date: The stock option is fully vested.

SEC source: 0001209191-21-029080 · doc4.xml · derivative · entry 2

Trenschel Robert J. · CIK 0001849917 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,182

Underlying: Common Stock · 10,182 shares

Expires 2029-04-25

F4 · price: Received in the Merger in exchange for a stock option to acquire 374,500 shares of LBS common stock for $1.12 per share.

F3 · derivative.exercise_date: The stock option vested according to the following schedule: 25% of the shares underlying the option vested on the grant date and the remaining 75% vested in three equal quarterly installments thereafter beginning on June 30, 2019.

SEC source: 0001209191-21-029080 · doc4.xml · nonDerivative · entry 1

Trenschel Robert J. · CIK 0001849917 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Yuma Regional Medical Center

Disclosed balance after: 304,479

F1 · price: Received in exchange for 11,198,208 shares of common stock of Leading BioSciences, Inc. ("LBS"), pursuant to the Agreement and Plan of Merger, dated December 16, 2020, among Seneca Biopharma Inc., Townsgate Acquisition Sub 1, Inc. and LBS (the "Merger"). Per the terms of the Merger, each share of LBS's common stock was converted into the right to receive 0.02719 shares of Seneca's common stock. In the Merger, the name of the Issuer was changed from Seneca Biopharma, Inc. to Palisade Bio, Inc.

F2 · ownership.nature: The Reporting Person is the President and Chief Executive Officer of Yuma Regional Medical Center and shares voting and investment power over the securities held by Yuma Regional Medical Center.

SEC source: 0001209191-21-029076 · doc4.xml · derivative · entry 13

Hallam Thomas · CIK 0001850921 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,190

Underlying: Common Stock · 27,190 shares

Expires 2031-04-26

F20 · price: Received in the Merger in exchange for a stock option to acquire 1,000,000 shares of LBS common stock for $0.48 per share.

F8 · derivative.exercise_date: The stock option is fully vested.

SEC source: 0001209191-21-029076 · doc4.xml · derivative · entry 12

Hallam Thomas · CIK 0001850921 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,294

Underlying: Common Stock · 12,294 shares

Expires 2030-02-19

F19 · price: Received in the Merger in exchange for a stock option to acquire 452,200 shares of LBS common stock for $0.73 per share.

F6 · derivative.exercise_date: The option vests in 12 equal quarterly installments from the vesting commencement date.

SEC source: 0001209191-21-029076 · doc4.xml · derivative · entry 11

Hallam Thomas · CIK 0001850921 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,002

Underlying: Common Stock · 15,002 shares

Expires 2029-03-22

F18 · price: Received in the Merger in exchange for a stock option to acquire 551,753 shares of LBS common stock for $1.45 per share.

F17 · derivative.exercise_date: The stock option vests according to the following schedule: 67% of the shares underlying the option vests on the grant date and the remaining 33% vests in four equal quarterly installments thereafter beginning on March 31, 2019.

SEC source: 0001209191-21-029076 · doc4.xml · derivative · entry 10

Hallam Thomas · CIK 0001850921 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,392

Underlying: Common Stock · 20,392 shares

Expires 2029-03-22

F16 · price: Received in the Merger in exchange for a stock option to acquire 750,000 shares of LBS common stock for $1.12 per share.

F8 · derivative.exercise_date: The stock option is fully vested.

SEC source: 0001209191-21-029076 · doc4.xml · derivative · entry 9

Hallam Thomas · CIK 0001850921 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,754

Underlying: Common Stock · 8,754 shares

Expires 2029-03-22

F15 · price: Received in the Merger in exchange for a stock option to acquire 322,000 shares of LBS common stock for $1.12 per share.

F6 · derivative.exercise_date: The option vests in 12 equal quarterly installments from the vesting commencement date.

SEC source: 0001209191-21-029076 · doc4.xml · derivative · entry 8

Hallam Thomas · CIK 0001850921 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,730

Underlying: Common Stock · 22,730 shares

Expires 2029-03-22

F14 · price: Received in the Merger in exchange for a stock option to acquire 836,000 shares of LBS common stock for $1.12 per share.

F13 · derivative.exercise_date: The stock option vests according to the following schedule: 67% of the shares underlying the option vests on the grant date and the remaining 33% vests in eight equal quarterly installments thereafter beginning on March 31, 2019.

SEC source: 0001209191-21-029076 · doc4.xml · derivative · entry 7

Hallam Thomas · CIK 0001850921 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 95,572

Underlying: Common Stock · 95,572 shares

Expires 2027-11-10

F12 · price: Received in the Merger in exchange for a stock option to acquire 3,515,000 shares of LBS common stock for $0.75 per share.

F11 · derivative.exercise_date: The stock option vests according to the following schedule: 25% of the shares underlying the option vests on grant date and the remaining 75% vests in nine equal quarterly installments thereafter beginning on January 1, 2018.

SEC source: 0001209191-21-029076 · doc4.xml · derivative · entry 6

Hallam Thomas · CIK 0001850921 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,719

Underlying: Common Stock · 2,719 shares

Expires 2027-11-10

F10 · price: Received in the Merger in exchange for a stock option to acquire 100,000 shares of LBS common stock for $0.75 per share.

F8 · derivative.exercise_date: The stock option is fully vested.

SEC source: 0001209191-21-029076 · doc4.xml · derivative · entry 5

Hallam Thomas · CIK 0001850921 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 477

Underlying: Common Stock · 477 shares

Expires 2024-02-02

F9 · price: Received in the Merger in exchange for a stock option to acquire 17,567 shares of LBS common stock for $0.75 per share.

F8 · derivative.exercise_date: The stock option is fully vested.

SEC source: 0001209191-21-029076 · doc4.xml · derivative · entry 4

Hallam Thomas · CIK 0001850921 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,797

Underlying: Common Stock · 6,797 shares

Expires 2025-02-02

F7 · price: Received in the Merger in exchange for a stock option to acquire 250,000 shares of LBS common stock for $0.75 per share.

F6 · derivative.exercise_date: The option vests in 12 equal quarterly installments from the vesting commencement date.

SEC source: 0001209191-21-029076 · doc4.xml · derivative · entry 3

Hallam Thomas · CIK 0001850921 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,189

Underlying: Common Stock · 27,189 shares

Expires 2023-10-01

F5 · price: Received in the Merger in exchange for a stock option to acquire 1,000,000 shares of LBS common stock for $0.50 per share.

F4 · derivative.exercise_date: The stock option vested according to the following schedule: 17% of the shares underlying the option vested on grant date and the remaining 83% vested in 10 equal quarterly installments thereafter beginning on June 30, 2014.

SEC source: 0001209191-21-029076 · doc4.xml · derivative · entry 2

Hallam Thomas · CIK 0001850921 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,078

Underlying: Common Stock · 4,078 shares

Expires 2022-10-10

F3 · price: Received in the Merger in exchange for a stock option to acquire 150,000 shares of LBS common stock for $0.40 per share.

F2 · derivative.exercise_date: The stock option vested according to the following schedule: 50% of the shares underlying the option vested on the grant date and the remaining 50% vested in six equal quarterly installments thereafter beginning on July 9, 2014.

SEC source: 0001209191-21-029076 · doc4.xml · nonDerivative · entry 1

Hallam Thomas · CIK 0001850921 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,592

F1 · price: The Reporting Person acquired the shares of the Issuer in exchange for 58,582 shares of common stock of Leading BioSciences, Inc. ("LBS"), pursuant to the Agreement and Plan of Merger, dated December 16, 2020, among Seneca Biopharma Inc., Townsgate Acquisition Sub 1, Inc. and LBS (the "Merger"). Per the terms of the Merger, each share of LBS's common stock was converted into the right to receive 0.02719 shares of Seneca's common stock. In the Merger, the name of the Issuer was changed from Seneca Biopharma, Inc. to Palisade Bio, Inc.

SEC source: 0001209191-21-029073 · doc4.xml · derivative · entry 21

Finley John David · CIK 0001851034 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By FCW Investments LLC

Disclosed balance after: 293

Underlying: Common Stock · 293 shares

Expires 2028-06-30

F28 · price: Received in the Merger in exchange for a warrant to purchase 10,787 shares of LBS common stock for $1.12 per share.

F3 · ownership.nature: The Reporting Person is the managing member of FCW Investments LLC and has sole investment and voting power over the securities held by this entity.

SEC source: 0001209191-21-029073 · doc4.xml · derivative · entry 20

Finley John David · CIK 0001851034 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By FCW Investments LLC

Disclosed balance after: 325

Underlying: Common Stock · 325 shares

Expires 2028-12-31

F27 · price: Received in the Merger in exchange for a warrant to purchase 11,994 shares of LBS common stock for $1.12 per share.

F3 · ownership.nature: The Reporting Person is the managing member of FCW Investments LLC and has sole investment and voting power over the securities held by this entity.

SEC source: 0001209191-21-029073 · doc4.xml · derivative · entry 19

Finley John David · CIK 0001851034 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By FCW Investments LLC

Disclosed balance after: 27

Underlying: Common Stock · 27 shares

Expires 2028-04-16

F26 · price: Received in the Merger in exchange for a warrant to purchase 1,000 shares of LBS common stock for $0.75 per share.

F3 · ownership.nature: The Reporting Person is the managing member of FCW Investments LLC and has sole investment and voting power over the securities held by this entity.

SEC source: 0001209191-21-029073 · doc4.xml · derivative · entry 18

Finley John David · CIK 0001851034 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By FCW Investments LLC

Disclosed balance after: 516

Underlying: Common Stock · 516 shares

Expires 2028-03-20

F25 · price: Received in the Merger in exchange for a warrant to purchase 19,000 shares of LBS common stock for $0.75 per share.

F3 · ownership.nature: The Reporting Person is the managing member of FCW Investments LLC and has sole investment and voting power over the securities held by this entity.

SEC source: 0001209191-21-029073 · doc4.xml · derivative · entry 17

Finley John David · CIK 0001851034 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By FCW Investments LLC

Disclosed balance after: 40

Underlying: Common Stock · 40 shares

Expires 2028-01-01

F24 · price: Received in the Merger in exchange for a warrant to purchase 1,500 shares of LBS common stock for $0.75 per share.

F3 · ownership.nature: The Reporting Person is the managing member of FCW Investments LLC and has sole investment and voting power over the securities held by this entity.

SEC source: 0001209191-21-029073 · doc4.xml · derivative · entry 16

Finley John David · CIK 0001851034 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By FCW Investments LLC

Disclosed balance after: 503

Underlying: Common Stock · 503 shares

Expires 2027-06-14

F23 · price: Received in the Merger in exchange for a warrant to purchase 18,500 shares of LBS common stock for $0.75 per share.

F3 · ownership.nature: The Reporting Person is the managing member of FCW Investments LLC and has sole investment and voting power over the securities held by this entity.

SEC source: 0001209191-21-029073 · doc4.xml · derivative · entry 15

Finley John David · CIK 0001851034 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 339

Underlying: Common Stock · 339 shares

Expires 2026-09-02

F22 · price: Received in the Merger in exchange for a warrant to purchase 12,500 shares of LBS common stock for $0.75 per share.

SEC source: 0001209191-21-029073 · doc4.xml · derivative · entry 14

Finley John David · CIK 0001851034 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 49

Underlying: Common Stock · 49 shares

Expires 2028-06-30

F21 · price: Received in the Merger in exchange for a warrant to purchase 1,824 shares of LBS common stock for $1.12 per share.

SEC source: 0001209191-21-029073 · doc4.xml · derivative · entry 13

Finley John David · CIK 0001851034 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51

Underlying: Common Stock · 51 shares

Expires 2028-12-31

F20 · price: Received in the Merger in exchange for a warrant to purchase 1,894 shares of LBS common stock for $1.12 per share.

SEC source: 0001209191-21-029073 · doc4.xml · derivative · entry 12

Finley John David · CIK 0001851034 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 95

Underlying: Common Stock · 95 shares

Expires 2027-12-15

F19 · price: Received in the Merger in exchange for a warrant to purchase 3,500 shares of LBS common stock for $0.75 per share.

SEC source: 0001209191-21-029073 · doc4.xml · derivative · entry 11

Finley John David · CIK 0001851034 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,595

Underlying: Common Stock · 2,595 shares

Expires 2031-04-26

F18 · price: Received in the Merger in exchange for a stock option to acquire 95,463 shares of LBS common stock for $0.73 per share.

F4 · derivative.exercise_date: The stock option is fully vested.

SEC source: 0001209191-21-029073 · doc4.xml · derivative · entry 10

Finley John David · CIK 0001851034 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,952

Underlying: Common Stock · 7,952 shares

Expires 2030-02-19

F17 · price: Received in the Merger in exchange for a stock option to acquire 292,500 shares of LBS common stock for $0.73 per share.

F12 · derivative.exercise_date: The stock option vests in 12 equal quarterly installments from the vesting commencement date.

SEC source: 0001209191-21-029073 · doc4.xml · derivative · entry 9

Finley John David · CIK 0001851034 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,702

Underlying: Common Stock · 9,702 shares

Expires 2029-03-22

F16 · price: Received in the Merger in exchange for a stock option to acquire 356,855 shares of LBS common stock for $1.45 per share.

F15 · derivative.exercise_date: The stock option vests according to the following schedule: 67% of the shares underlying the option vests on grant date and the remaining 33% vests in four equal quarterly installments thereafter beginning on March 31, 2020.

SEC source: 0001209191-21-029073 · doc4.xml · derivative · entry 8

Finley John David · CIK 0001851034 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,033

Underlying: Common Stock · 19,033 shares

Expires 2029-03-22

F14 · price: Received in the Merger in exchange for a stock option to acquire 700,000 shares of LBS common stock for $1.12 per share.

F4 · derivative.exercise_date: The stock option is fully vested.

SEC source: 0001209191-21-029073 · doc4.xml · derivative · entry 7

Finley John David · CIK 0001851034 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,662

Underlying: Common Stock · 5,662 shares

Expires 2029-03-22

F13 · price: Received in the Merger in exchange for a stock option to acquire 208,300 shares of LBS common stock for $1.12 per share.

F12 · derivative.exercise_date: The stock option vests in 12 equal quarterly installments from the vesting commencement date.

SEC source: 0001209191-21-029073 · doc4.xml · derivative · entry 6

Finley John David · CIK 0001851034 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,708

Underlying: Common Stock · 14,708 shares

Expires 2029-03-22

F11 · price: Received in the Merger in exchange for a stock option to acquire 541,000 shares of LBS common stock for $1.12 per share.

F10 · derivative.exercise_date: The stock option vests according to the following schedule: 34% of the shares subject to the option vests on grant date and the remaining 66% vests in eight equal quarterly installments thereafter beginning on March 31, 2019.

SEC source: 0001209191-21-029073 · doc4.xml · derivative · entry 5

Finley John David · CIK 0001851034 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,068

Underlying: Common Stock · 52,068 shares

Expires 2027-11-10

F9 · price: Received in the Merger in exchange for a stock option to acquire 1,915,000 shares of LBS common stock for $0.75 per share.

F8 · derivative.exercise_date: The stock option vests according to the following schedule: 31% of the shares underlying the option vested on the grant date and the remaining 69% vests in nine equal quarterly installments thereafter beginning on January 1, 2018.

SEC source: 0001209191-21-029073 · doc4.xml · derivative · entry 4

Finley John David · CIK 0001851034 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,516

Underlying: Common Stock · 9,516 shares

Expires 2024-12-13

F7 · price: Received in the Merger in exchange for a stock option to acquire 350,000 shares of LBS common stock for $0.75 per share.

F6 · derivative.exercise_date: The stock option vested according to the following schedule: 58% of the shares underlying the option vested on the grant date and the remaining 62% vested in five equal quarterly installments thereafter beginning on December 12, 2016.

SEC source: 0001209191-21-029073 · doc4.xml · derivative · entry 3

Finley John David · CIK 0001851034 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,418

Underlying: Common Stock · 10,418 shares

Expires 2025-06-12

F5 · price: Received in the Merger in exchange for a stock option to acquire 383,200 shares of LBS common stock for $0.75 per share.

F4 · derivative.exercise_date: The stock option is fully vested.

SEC source: 0001209191-21-029073 · doc4.xml · nonDerivative · entry 2

Finley John David · CIK 0001851034 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By FCW Investments LLC

Disclosed balance after: 26,322

F2 · price: Received in the Merger in exchange for 968,098 shares of LBS common stock.

F3 · ownership.nature: The Reporting Person is the managing member of FCW Investments LLC and has sole investment and voting power over the securities held by this entity.

SEC source: 0001209191-21-029073 · doc4.xml · nonDerivative · entry 1

Finley John David · CIK 0001851034 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,396

F1 · price: The Reporting Person acquired the shares of the Issuer in exchange for 88,182 shares of common stock of Leading BioSciences, Inc. ("LBS"), pursuant to the Agreement and Plan of Merger, dated December 16, 2020, among Seneca Biopharma Inc., Townsgate Acquisition Sub 1, Inc. and LBS (the "Merger"). Per the terms of the Merger, each share of LBS's common stock was converted into the right to receive 0.02719 shares of Seneca's common stock. In the Merger, the name of the Issuer was changed from Seneca Biopharma, Inc. to Palisade Bio, Inc.

SEC source: 0001209191-21-029069 · doc4.xml · derivative · entry 2

Diaz Stephanie · CIK 0001850265 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,406

Underlying: Common Stock · 4,406 shares

Expires 2030-07-10

F4 · price: Received in the Merger in exchange for a stock option to acquire 162,069 shares of LBS common stock for $0.73 per share.

F3 · derivative.exercise_date: The stock option vests according to the following schedule: 25% of the shares underlying the option vests on grant date and the remaining 75% vests in three equal quarterly installments thereafter beginning September 30, 2020.

SEC source: 0001209191-21-029069 · doc4.xml · derivative · entry 1

Diaz Stephanie · CIK 0001850265 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,203

Underlying: Common Stock · 10,203 shares

Expires 2029-06-19

F2 · price: Received in exchange for a stock option to acquire 375,250 shares of common stock of Leading BioSciences, Inc. ("LBS") for $1.12 per share, pursuant to the Agreement and Plan of Merger, dated December 16, 2020, among Seneca Biopharma Inc., Townsgate Acquisition Sub 1, Inc. and LBS (the "Merger"). Per the terms of the Merger, each share of LBS's common stock was converted into the right to receive 0.02719 shares of Seneca's common stock. In the Merger, the name of the Issuer was changed from Seneca Biopharma, Inc. to Palisade Bio, Inc.

F1 · derivative.exercise_date: The stock option vested in four equal quarterly installments from June 30, 2019.

SEC source: 0001209191-21-029081 · doc4.xml · derivative · entry 2

Williams Donald Allen · CIK 0001620013 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,406

Underlying: Common Stock · 4,406 shares

Expires 2030-07-10

F4 · price: Received in the Merger in exchange for a stock option to acquire 162,069 shares of LBS common stock for $0.73 per share.

F3 · derivative.exercise_date: The stock option vests according to the following schedule: 25% of the shares underlying the option vests on grant date and the remaining 75% vests in three equal quarterly installments thereafter beginning on September 30, 2020.

SEC source: 0001209191-21-029081 · doc4.xml · derivative · entry 1

Williams Donald Allen · CIK 0001620013 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,203

Underlying: Common Stock · 10,203 shares

Expires 2029-06-19

F2 · price: Received in exchange for a stock option to acquire 375,250 shares of common stock of Leading BioSciences, Inc. ("LBS") for $1.12 per share, pursuant to the Agreement and Plan of Merger, dated December 16, 2020, among Seneca Biopharma Inc., Townsgate Acquisition Sub 1, Inc. and LBS (the "Merger"). Per the terms of the Merger, each share of LBS's common stock was converted into the right to receive 0.02719 shares of Seneca's common stock. In the Merger, the name of the Issuer was changed from Seneca Biopharma, Inc. to Palisade Bio, Inc.

F1 · derivative.exercise_date: The stock option vested in four equal quarterly installments from June 30, 2019.